Article Information
History
- July 22, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Delphine Planas1,2,✉,
- Isabelle Staropoli1,
- Françoise Porot1,
- Florence Guivel-Benhassine1,
- Lynda Handala3,4,
- Mathieu Prot5,
- William-Henry Bolland1,6,
- Julien Puech7,
- Hélène Péré7,8,
- David Veyer7,8,
- Aymeric Sève9,
- Etienne-Simon-Lorière5,
- Timothée Bruel1,2,
- Thierry Prazuck9,
- Karl Stefic3,4,
- Laurent Hocqueloux9,* and
- Olivier Schwartz1,2,*,✉
- 1Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France
- 2Vaccine Research Institute, Créteil, France
- 3INSERM U1259, Université de Tours, Tours, France
- 4CHRU de Tours, National Reference Center for HIV-Associated laboratory, Tours, France
- 5G5 Evolutionary Genomics of RNA Viruses, Institut Pasteur, Université Paris Cité, Paris, France
- 6École Doctorale BioSPC 562, Université de Paris, Paris, France
- 7Laboratoire de Virologie, Service de Microbiologie, Hôpital Européen Georges Pompidou, Paris, France
- 8Functional Genomics of Solid Tumors (FunGeST), Centre de Recherche des Cordeliers, INSERM, Université de Paris, Sorbonne Université, Paris, France
- 9Service de Maladies Infectieuses, CHR d’Orléans, Orléans, France
- ↵✉Correspondance : delphine.planas{at}pasteur.fr & olivier.schwartz{at}pasteur.fr
Posted July 22, 2022.
Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without Omicron breakthrough infection
